Publication details

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

Investor logo
Authors

WEINBERGEROVÁ Barbora MAYER Jiří KABUT Tomas SPERR Wolfgang R STEVKOVA Jana JONASOVA Anna CERNAN Martin HERNDLHOFER Susanne ORAVCOVA Iveta SRAMEK Jiri NOVAK Jan ŠTĚPÁNOVÁ Radka SZOTKOWSKI Tomas DRGONA Lubos ZAK Pavel VALENT Peter

Year of publication 2024
Type Article in Periodical
Magazine / Source British journal of haematology
MU Faculty or unit

Faculty of Medicine

Citation
web https://onlinelibrary.wiley.com/doi/10.1111/bjh.19670
Doi http://dx.doi.org/10.1111/bjh.19670
Keywords acute myeloid leukaemia; antifungal prophylaxis; fungal infection; venetoclax and azacitidine
Attached files
Description Our observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first-line venetoclax and azacitidine (VEN + AZA)-treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment-cycle and did not affect patients' overall outcome.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info